Become a Member/Get Newsletter
Search All Papers
What We Know
Drugs in Trials
Institutes and Labs
How to Cite
The Schizophrenia Research Forum web site is sponsored by
, the Brain and Behavior Research Fund, and was created with funding from the
U.S. National Institute of Mental Health
SZGene - Gene overview of all published SZ-association studies for MAPK14
(RK; p38; EXIP; Mxi2; CSBP1; CSBP2; CSPB1; PRKM14; PRKM15; SAPK2A)
mitogen-activated protein kinase 14
(p38alpha Exip; p38 MAP kinase; MAP kinase Mxi2; Csaids binding protein; MAX-interacting protein 2; stress-activated protein kinase 2A; p38 mitogen activated protein kinase; cytokine suppressive anti-inflammatory drug binding protein)
Updated 8 May 2008
1. Case-Control Studies (by ethnic group)
46.5 + 12.7
44.9 + 10.9
if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
Number of polymorphisms tested per gene and per sample.
Onset Age and Age:
Mean or median age at onset or examination, respectively.
Criteria used to determine SZ diagnosis -> "IIIR"(DSM-IIIR), "IV" (DSM-IV), "9" (ICD-9), "10" (ICD-10), "M" (Mixed), "RDC" (Research Diagnostic Criteria), "U" (Unknown).
Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
: Either no data provided or in case of overlap, data included in original study.
SZGene Recent Updates
An up-to-date collection of all published genetic association studies.
Reset Text Size
Email this page
Copyright © 2005-2022 Schizophrenia Research Forum